\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand*\HyPL@Entry[1]{}
\HyPL@Entry{0<</S/D>>}
\@writefile{toc}{\contentsline {section}{\numberline {1}Section 1: Feature Engineering and Scenario Ablation Analysis}{2}{section.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {1.1}Ablation Study 1: Feature Space Hybridization}{2}{subsection.1.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {1.2}Ablation Study 2: Dimensionality Optimization and Computational Efficiency}{2}{subsection.1.2}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {1}{\ignorespaces Performance comparison of different feature representations for disease gene prioritization across seven complex diseases.}}{3}{table.1}\protected@file@percent }
\newlabel{tab:final_scenario_comparison}{{1}{3}{Performance comparison of different feature representations for disease gene prioritization across seven complex diseases}{table.1}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2}{\ignorespaces Hyperparameter settings for Node2Vec embedding configurations used in the study.}}{4}{table.2}\protected@file@percent }
\newlabel{tab:hyperparameters}{{2}{4}{Hyperparameter settings for Node2Vec embedding configurations used in the study}{table.2}{}}
\@writefile{toc}{\contentsline {section}{\numberline {2}Section 2: Comprehensive Performance Evaluation Tables}{4}{section.2}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Evaluation Metrics and Methodological Summary}{4}{subsection.2.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}Aggregated Performance Profiles Across Disease Modules}{4}{subsection.2.2}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {3}{\ignorespaces Performance comparison of node2vec embedding configurations across seven complex diseases.}}{5}{table.3}\protected@file@percent }
\newlabel{tab:embedding_results}{{3}{5}{Performance comparison of node2vec embedding configurations across seven complex diseases}{table.3}{}}
\@writefile{lot}{\contentsline {table}{\numberline {4}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Malignant Neoplasm of Breast (C0006142)}}}{5}{table.4}\protected@file@percent }
\newlabel{tab:table_s1}{{4}{5}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Malignant Neoplasm of Breast (C0006142)}}{table.4}{}}
\@writefile{lot}{\contentsline {table}{\numberline {5}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Schizophrenia (0036341)}.}}{6}{table.5}\protected@file@percent }
\newlabel{tab:table_s2}{{5}{6}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Schizophrenia (0036341)}}{table.5}{}}
\@writefile{lot}{\contentsline {table}{\numberline {6}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Liver Cirrhosis (C0023893)}.}}{6}{table.6}\protected@file@percent }
\newlabel{tab:table_s3}{{6}{6}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Liver Cirrhosis (C0023893)}}{table.6}{}}
\@writefile{lot}{\contentsline {table}{\numberline {7}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Colorectal Carcinoma (C0009402)}.}}{6}{table.7}\protected@file@percent }
\newlabel{tab:table_s4}{{7}{6}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Colorectal Carcinoma (C0009402)}}{table.7}{}}
\@writefile{lot}{\contentsline {table}{\numberline {8}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Malignant Neoplasm of Prostate (C0376358)}.}}{6}{table.8}\protected@file@percent }
\newlabel{tab:table_s5}{{8}{6}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Malignant Neoplasm of Prostate (C0376358)}}{table.8}{}}
\@writefile{lot}{\contentsline {table}{\numberline {9}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Intellectual Disability (C3714756)}.}}{7}{table.9}\protected@file@percent }
\newlabel{tab:table_s6}{{9}{7}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Intellectual Disability (C3714756)}}{table.9}{}}
\@writefile{lot}{\contentsline {table}{\numberline {10}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Bipolar Disorder (C0005586)}.}}{7}{table.10}\protected@file@percent }
\newlabel{tab:table_s7}{{10}{7}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Bipolar Disorder (C0005586)}}{table.10}{}}
\@writefile{lot}{\contentsline {table}{\numberline {11}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Drug-Induced Liver Disease (C0860207)}.}}{7}{table.11}\protected@file@percent }
\newlabel{tab:table_s8}{{11}{7}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Drug-Induced Liver Disease (C0860207)}}{table.11}{}}
\@writefile{lot}{\contentsline {table}{\numberline {12}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Depressive Disorder (C0011581)}.}}{7}{table.12}\protected@file@percent }
\newlabel{tab:table_s9}{{12}{7}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Depressive Disorder (C0011581)}}{table.12}{}}
\@writefile{lot}{\contentsline {table}{\numberline {13}{\ignorespaces Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf  {Chronic Alcoholic Intoxication (C0001973)}.}}{8}{table.13}\protected@file@percent }
\newlabel{tab:table_s10}{{13}{8}{Macro-averaged performance evaluation across the complete $K$ threshold spectrum ($K \in [25, 50, 100, 200, 500, 750,$ $1000, 1500, 2000, 2500, 3000]$) for \textbf {Chronic Alcoholic Intoxication (C0001973)}}{table.13}{}}
\@writefile{toc}{\contentsline {section}{\numberline {3}Section 3: Top-$K$ Threshold Comparative Analysis}{8}{section.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Methodological Context and Robustness Evaluation}{8}{subsection.3.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}Sequential Threshold Performance Plots}{9}{subsection.3.2}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 25$.}}{9}{figure.1}\protected@file@percent }
\newlabel{fig:k25}{{1}{9}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 25$}{figure.1}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 50$.}}{9}{figure.2}\protected@file@percent }
\newlabel{fig:k50}{{2}{9}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 50$}{figure.2}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 100$.}}{10}{figure.3}\protected@file@percent }
\newlabel{fig:k100}{{3}{10}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 100$}{figure.3}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 200$.}}{10}{figure.4}\protected@file@percent }
\newlabel{fig:k200}{{4}{10}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 200$}{figure.4}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 500$.}}{11}{figure.5}\protected@file@percent }
\newlabel{fig:k500}{{5}{11}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 500$}{figure.5}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 750$.}}{11}{figure.6}\protected@file@percent }
\newlabel{fig:k750}{{6}{11}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 750$}{figure.6}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {7}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 1000$.}}{12}{figure.7}\protected@file@percent }
\newlabel{fig:k1000}{{7}{12}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 1000$}{figure.7}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {8}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 1500$.}}{12}{figure.8}\protected@file@percent }
\newlabel{fig:k1500}{{8}{12}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 1500$}{figure.8}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {9}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 2000$.}}{13}{figure.9}\protected@file@percent }
\newlabel{fig:k2000}{{9}{13}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 2000$}{figure.9}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {10}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 2500$.}}{13}{figure.10}\protected@file@percent }
\newlabel{fig:k2500}{{10}{13}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 2500$}{figure.10}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {11}{\ignorespaces Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 3000$.}}{14}{figure.11}\protected@file@percent }
\newlabel{fig:k3000}{{11}{14}{Comparative evaluation metrics across all ten complex diseases for top-$K$ threshold $K = 3000$}{figure.11}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4}Section 4: Continuous $F_1$-Score Trajectory Analysis across Top-$K$ Thresholds}{14}{section.4}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.1}Methodological Context and Cross-Disease Trends}{14}{subsection.4.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.2}Disease-Specific $F_1$-Score Comparison Curves}{14}{subsection.4.2}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {12}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Malignant Neoplasm of Breast.}}{15}{figure.12}\protected@file@percent }
\newlabel{fig:f1_breast}{{12}{15}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Malignant Neoplasm of Breast}{figure.12}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {13}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Schizophrenia.}}{15}{figure.13}\protected@file@percent }
\newlabel{fig:f1_schizophrenia}{{13}{15}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Schizophrenia}{figure.13}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {14}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Liver Cirrhosis.}}{16}{figure.14}\protected@file@percent }
\newlabel{fig:f1_liver_cirrhosis}{{14}{16}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Liver Cirrhosis}{figure.14}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {15}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Colorectal Carcinoma.}}{16}{figure.15}\protected@file@percent }
\newlabel{fig:f1_colorectal}{{15}{16}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Colorectal Carcinoma}{figure.15}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {16}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Malignant Neoplasm of Prostate.}}{17}{figure.16}\protected@file@percent }
\newlabel{fig:f1_prostate}{{16}{17}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Malignant Neoplasm of Prostate}{figure.16}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {17}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Bipolar Disorder.}}{17}{figure.17}\protected@file@percent }
\newlabel{fig:f1_bipolar}{{17}{17}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Bipolar Disorder}{figure.17}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {18}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Drug-Induced Liver Disease.}}{18}{figure.18}\protected@file@percent }
\newlabel{fig:f1_drug_liver}{{18}{18}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Drug-Induced Liver Disease}{figure.18}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {19}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Depressive Disorder.}}{18}{figure.19}\protected@file@percent }
\newlabel{fig:f1_depression}{{19}{18}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Depressive Disorder}{figure.19}{}}
\gdef \LT@i {\LT@entry 
    {1}{120.12054pt}\LT@entry 
    {1}{103.04872pt}\LT@entry 
    {1}{205.47882pt}\LT@entry 
    {1}{74.59596pt}}
\@writefile{lof}{\contentsline {figure}{\numberline {20}{\ignorespaces Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Chronic Alcoholic Intoxication.}}{19}{figure.20}\protected@file@percent }
\newlabel{fig:f1_alcoholic}{{20}{19}{Continuous $F_1$-score trajectory comparison across varying top-$K$ thresholds for Chronic Alcoholic Intoxication}{figure.20}{}}
\@writefile{toc}{\contentsline {section}{\numberline {5}Section 5: Enrichment Analysis}{19}{section.5}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {14}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease.}}{19}{table.14}\protected@file@percent }
\newlabel{tab:enrichment_analysis}{{14}{19}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease}{table.14}{}}
\@writefile{lot}{\contentsline {table}{\numberline {14}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease.}}{20}{table.14}\protected@file@percent }
\newlabel{tab:enrichment_analysis}{{14}{20}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease}{table.14}{}}
\@writefile{lot}{\contentsline {table}{\numberline {14}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease.}}{21}{table.14}\protected@file@percent }
\newlabel{tab:enrichment_analysis}{{14}{21}{Enrichment analysis for the considered diseases. We report the most enriched GO, pathway, or disease}{table.14}{}}
\bibcite{seeler2017}{1}
\bibcite{hendriks2016}{2}
\bibcite{owen2016}{3}
\bibcite{kahn2015}{4}
\bibcite{bataller2005liver}{5}
\bibcite{kisseleva2021}{6}
\bibcite{fearon1990}{7}
\bibcite{liebl2021}{8}
\bibcite{drake2014}{9}
\bibcite{sfanos2012}{10}
\bibcite{mossink2021}{11}
\bibcite{ciptasari2020}{12}
\bibcite{grande2016}{13}
\bibcite{fornito2015}{14}
\bibcite{zimmerman2000}{15}
\bibcite{stravitz2019}{16}
\bibcite{krystal2019}{17}
\bibcite{luscher2011}{18}
\bibcite{golaszewski2026}{19}
\bibcite{spanagel2009}{20}
\gdef \@abspage@last{23}
